

# M17: Bone Marrow Cellularity

Study Number: I20045

Test Compound: Phenanthrene

Date: 03 Sep 2024

DTTID: 103-005-012-000-2

CAS Number: 85-01-8

Time: 2:33:23 PM

Study Type: Immune screening

DTXSID: DTXSID6024254

Species/Strain: Mouse/B6C3F1/N

Females: Immunopath Cohort

	Treatment Groups							
	0 mg/kg	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg	400 mg/kg	50 mg/kg CPS
Bone Marrow Cells ( $\times 10^6$ )	11.356 $\pm$ 0.671[8]	11.908 $\pm$ 1.220[8]	11.560 $\pm$ 1.320[6]	10.434 $\pm$ 1.084[5]	10.082 $\pm$ 0.427[5]	10.707 $\pm$ 1.007[7]	12.623 $\pm$ 1.437[8]	4.018 $\pm$ 0.256[8]**

# M17: Bone Marrow Cellularity

Study Number: I20045

Test Compound: Phenanthrene

Date: 03 Sep 2024

DTTID: 103-005-012-000-2

CAS Number: 85-01-8

Time: 2:33:23 PM

Study Type: Immune screening

DTXSID: DTXSID6024254

Species/Strain: Mouse/B6C3F1/N

## LEGEND

Data are displayed as mean  $\pm$  SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests. The positive control group (50 mg/kg CPS) was excluded from trend test.

Statistical analysis for the positive control group (50 mg/kg CPS) compared to the vehicle control group was performed using the Wilcoxon rank sum test.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

SD = Study Day

SEM = Standard Error of the Mean

CPS = Cyclophosphamide

Females from the vehicle control and treatment groups were removed on SD 28.

\*\* END OF REPORT \*\*